Cancer Cachexia: Drug Development Pipeline Study, H1 2018
Cancer Cachexia pipeline comprises of 17 drugs under development as of March 2018. Of these, 1 drug is in Phase 1 and 4 drugs in phase 2 with 1 drug in Phase 3. Further, 10 drugs are in Pre-clinical stage and 1 drug is in research phase.
26 companies are developing the pipeline for Cancer Cachexia. Of this, Helsinn Healthcare, S.A has the most advanced stage drug in pipeline. Ghrelin receptor is the most targeted area for most compounds.
No compounds have been awarded orphan drug status for PAH.
Anorexia/Cachexia Syndrome is a serious complication in patients with advanced cancer where the patients witness a wasting syndrome caused by Anorexia and loss of weight. The market is estimated to be around $2 billion. While Anorexia refers to loss of appetite, the term Cachexia corresponds to weight loss including lean body mass and fat.
Around 5 million people are estimated to be affected by Anorexia/Cachexia and most of the patients have a short survival time. Further, these patients react poorly against chemotherapy treatments. Body composition changes are also observed in the patients including muscle wasting and lean tissue decrease.
The most comprehensive pipeline review “Cancer Cachexia- Drug Development Pipeline Study” provides in-depth analysis and update information on Cancer Cachexia pipeline drugs. Current status of all the drugs in the Cancer Cachexia pipeline is provided in the research work.
The report provides detailed analysis of Cancer Cachexia pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Cancer Cachexia report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Cancer Cachexia industry.
Scope:
26 companies are developing the pipeline for Cancer Cachexia. Of this, Helsinn Healthcare, S.A has the most advanced stage drug in pipeline. Ghrelin receptor is the most targeted area for most compounds.
No compounds have been awarded orphan drug status for PAH.
Anorexia/Cachexia Syndrome is a serious complication in patients with advanced cancer where the patients witness a wasting syndrome caused by Anorexia and loss of weight. The market is estimated to be around $2 billion. While Anorexia refers to loss of appetite, the term Cachexia corresponds to weight loss including lean body mass and fat.
Around 5 million people are estimated to be affected by Anorexia/Cachexia and most of the patients have a short survival time. Further, these patients react poorly against chemotherapy treatments. Body composition changes are also observed in the patients including muscle wasting and lean tissue decrease.
The most comprehensive pipeline review “Cancer Cachexia- Drug Development Pipeline Study” provides in-depth analysis and update information on Cancer Cachexia pipeline drugs. Current status of all the drugs in the Cancer Cachexia pipeline is provided in the research work.
The report provides detailed analysis of Cancer Cachexia pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Cancer Cachexia report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Cancer Cachexia industry.
Scope:
- - All latest industry developments and their impact on projects and companies
- - Complete overview of global Cancer Cachexia therapy options and treatments
- - The pipeline study reviews drug details for Cancer Cachexia by developing companies, institutions, mechanism of action, Target, Route, Phase (pre-clinical/ Discovery, Phase 1, Phase 2, Phase 3, Pre-Registration, IND/ NDA), molecule
- - Mergers, Acquisitions, licensing, co-development and project acquisition news for Cancer Cachexia market
- - Cancer Cachexia drugs being developed in combination with other drugs are also detailed
- - Company wise drugs listed with their current status, partners and news updates
1 TABLE OF CONTENTS
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 CANCER CACHEXIA- COMPANY WISE PIPELINE ANALYSIS
3.1 ABREOS BIOSCIENCES, INC. PIPELINE, H1 2018
3.2 AAVOGEN PIPELINE, H1 2018
3.3 ACACIA PHARMA PIPELINE, H1 2018
3.4 AETERNA ZENTARIS INC. PIPELINE, H1 2018
3.5 AVEO ONCOLOGY PIPELINE, H1 2018
3.6 ENERGENESIS BIOMEDICAL CO., LTD PIPELINE, H1 2018
3.7 EXTEND BIOSCIENCES PIPELINE, H1 2018
3.8 HELSINN HEALTHCARE, S.A PIPELINE, H1 2018
3.9 INCYTE CORPORATION PIPELINE, H1 2018
3.10 NEOMED PIPELINE, H1 2018
3.11 NGM BIOPHARMACEUTICALS PIPELINE, H1 2018
3.12 PARADIGM BIOPHARMA PIPELINE, H1 2018
3.13 RAQUALIA PHARMA PIPELINE, H1 2018
3.14 STEMMED LTD PIPELINE, H1 2018
3.15 TCI PEPTIDE THERAPEUTICS PIPELINE, H1 2018
3.16 VIKING THERAPEUTICS PIPELINE, H1 2018
4 CANCER CACHEXIA DRUG SNAPSHOTS
4.1 CRYPTIC-FC DRUG DETAILS
4.1.1 Snapshot
4.1.2 Overview
4.1.3 Mechanism of Action
4.1.4 Current Status
4.1.5 Trial Details
4.2 APD209DRUG DETAILS
4.2.1 Snapshot
4.2.2 Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.2.5 Trial Details
4.3 MACIMORELIN DRUG DETAILS
4.3.1 Snapshot
4.3.2 Overview
4.3.3 Mechanism of Action
4.3.4 Current Status
4.3.5 Trial Details
4.4 RUXOLITINIB PHOSPHATE DRUG DETAILS
4.4.1 Snapshot
4.4.2 Overview
4.4.3 Mechanism of Action
4.4.4 Current Status
4.4.5 Trial Details
4.5 AV-380 DRUG DETAILS
4.5.1 Snapshot
4.5.2 Overview
4.5.3 Mechanism of Action
4.5.4 Current Status
4.5.5 Trial Details
4.6 IP1510 DRUG DETAILS
4.6.1 Snapshot
4.6.2 Overview
4.6.3 Mechanism of Action
4.6.4 Current Status
4.6.5 Trial Details
4.7 RQ-00433412 DRUG DETAILS
4.7.1 Snapshot
4.7.2 Overview
4.7.3 Mechanism of Action
4.7.4 Current Status
4.8 VK 5211 DRUG DETAILS
4.8.1 Snapshot
4.8.2 Overview
4.8.3 Mechanism of Action
4.8.4 Current Status
4.8.5 Trial Details
4.9 ANAMORELIN DRUG DETAILS
4.9.1 Snapshot
4.9.2 Overview
4.9.3 Mechanism of Action
4.9.4 Current Status
4.9.5 Trial Details
4.10 HM03 DRUG DETAILS
4.10.1 Snapshot
4.10.2 Overview
4.10.3 Mechanism of Action
4.10.4 Current Status
4.11 AVGN7 DRUG DETAILS
4.11.1 Snapshot
4.11.2 Overview
4.11.3 Mechanism of Action
4.11.4 Current Status
4.11.5 Trial Details
4.12 C188-9 DRUG DETAILS
4.12.1 Snapshot
4.12.2 Overview
4.12.3 Mechanism of Action
4.12.4 Current Status
4.13 ENERGI-F706 DRUG DETAILS
4.13.1 Snapshot
4.13.2 Overview
4.13.3 Mechanism of Action
4.13.4 Current Status
4.13.5 Trial Details
4.14 EXT 400-GHRELIN DRUG DETAILS
4.14.1 Snapshot
4.14.2 Overview
4.14.3 Mechanism of Action
4.14.4 Current Status
4.15 NEO1940 DRUG DETAILS
4.15.1 Snapshot
4.15.2 Overview
4.15.3 Mechanism of Action
4.15.4 Current Status
4.16 CANCER CACHEXIA THERAPEUTIC DRUG DETAILS
4.16.1 Snapshot
4.16.2 Overview
4.16.3 Mechanism of Action
4.16.4 Current Status
4.17 NGM120 DRUG DETAILS
4.17.1 Snapshot
4.17.2 Overview
4.17.3 Mechanism of Action
4.17.4 Current Status
4.17.5 Trial Details
5 RECENT DEVELOPMENTS IN CANCER CACHEXIA PIPELINE
5.1 PROMISING NEW DRUG DEVELOPMENT COULD HELP TREAT CACHEXIA - APRIL 2017
5.2 POTENTIAL TARGET FOR TREATING CANCER CACHEXIA - OCTOBER 2017
5.3 SCIENTISTS BLOCK CANCER-INDUCED CACHEXIA IN PRECLINICAL TRIALS - OCTOBER 2017
6 APPENDIX
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 CANCER CACHEXIA- COMPANY WISE PIPELINE ANALYSIS
3.1 ABREOS BIOSCIENCES, INC. PIPELINE, H1 2018
3.2 AAVOGEN PIPELINE, H1 2018
3.3 ACACIA PHARMA PIPELINE, H1 2018
3.4 AETERNA ZENTARIS INC. PIPELINE, H1 2018
3.5 AVEO ONCOLOGY PIPELINE, H1 2018
3.6 ENERGENESIS BIOMEDICAL CO., LTD PIPELINE, H1 2018
3.7 EXTEND BIOSCIENCES PIPELINE, H1 2018
3.8 HELSINN HEALTHCARE, S.A PIPELINE, H1 2018
3.9 INCYTE CORPORATION PIPELINE, H1 2018
3.10 NEOMED PIPELINE, H1 2018
3.11 NGM BIOPHARMACEUTICALS PIPELINE, H1 2018
3.12 PARADIGM BIOPHARMA PIPELINE, H1 2018
3.13 RAQUALIA PHARMA PIPELINE, H1 2018
3.14 STEMMED LTD PIPELINE, H1 2018
3.15 TCI PEPTIDE THERAPEUTICS PIPELINE, H1 2018
3.16 VIKING THERAPEUTICS PIPELINE, H1 2018
4 CANCER CACHEXIA DRUG SNAPSHOTS
4.1 CRYPTIC-FC DRUG DETAILS
4.1.1 Snapshot
4.1.2 Overview
4.1.3 Mechanism of Action
4.1.4 Current Status
4.1.5 Trial Details
4.2 APD209DRUG DETAILS
4.2.1 Snapshot
4.2.2 Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.2.5 Trial Details
4.3 MACIMORELIN DRUG DETAILS
4.3.1 Snapshot
4.3.2 Overview
4.3.3 Mechanism of Action
4.3.4 Current Status
4.3.5 Trial Details
4.4 RUXOLITINIB PHOSPHATE DRUG DETAILS
4.4.1 Snapshot
4.4.2 Overview
4.4.3 Mechanism of Action
4.4.4 Current Status
4.4.5 Trial Details
4.5 AV-380 DRUG DETAILS
4.5.1 Snapshot
4.5.2 Overview
4.5.3 Mechanism of Action
4.5.4 Current Status
4.5.5 Trial Details
4.6 IP1510 DRUG DETAILS
4.6.1 Snapshot
4.6.2 Overview
4.6.3 Mechanism of Action
4.6.4 Current Status
4.6.5 Trial Details
4.7 RQ-00433412 DRUG DETAILS
4.7.1 Snapshot
4.7.2 Overview
4.7.3 Mechanism of Action
4.7.4 Current Status
4.8 VK 5211 DRUG DETAILS
4.8.1 Snapshot
4.8.2 Overview
4.8.3 Mechanism of Action
4.8.4 Current Status
4.8.5 Trial Details
4.9 ANAMORELIN DRUG DETAILS
4.9.1 Snapshot
4.9.2 Overview
4.9.3 Mechanism of Action
4.9.4 Current Status
4.9.5 Trial Details
4.10 HM03 DRUG DETAILS
4.10.1 Snapshot
4.10.2 Overview
4.10.3 Mechanism of Action
4.10.4 Current Status
4.11 AVGN7 DRUG DETAILS
4.11.1 Snapshot
4.11.2 Overview
4.11.3 Mechanism of Action
4.11.4 Current Status
4.11.5 Trial Details
4.12 C188-9 DRUG DETAILS
4.12.1 Snapshot
4.12.2 Overview
4.12.3 Mechanism of Action
4.12.4 Current Status
4.13 ENERGI-F706 DRUG DETAILS
4.13.1 Snapshot
4.13.2 Overview
4.13.3 Mechanism of Action
4.13.4 Current Status
4.13.5 Trial Details
4.14 EXT 400-GHRELIN DRUG DETAILS
4.14.1 Snapshot
4.14.2 Overview
4.14.3 Mechanism of Action
4.14.4 Current Status
4.15 NEO1940 DRUG DETAILS
4.15.1 Snapshot
4.15.2 Overview
4.15.3 Mechanism of Action
4.15.4 Current Status
4.16 CANCER CACHEXIA THERAPEUTIC DRUG DETAILS
4.16.1 Snapshot
4.16.2 Overview
4.16.3 Mechanism of Action
4.16.4 Current Status
4.17 NGM120 DRUG DETAILS
4.17.1 Snapshot
4.17.2 Overview
4.17.3 Mechanism of Action
4.17.4 Current Status
4.17.5 Trial Details
5 RECENT DEVELOPMENTS IN CANCER CACHEXIA PIPELINE
5.1 PROMISING NEW DRUG DEVELOPMENT COULD HELP TREAT CACHEXIA - APRIL 2017
5.2 POTENTIAL TARGET FOR TREATING CANCER CACHEXIA - OCTOBER 2017
5.3 SCIENTISTS BLOCK CANCER-INDUCED CACHEXIA IN PRECLINICAL TRIALS - OCTOBER 2017
6 APPENDIX
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY
LIST OF FIGURES
Figure 1: Cancer Cachexia Pipeline by Phase, H1- 2018
Figure 2: Cancer Cachexia Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Cancer Cachexia Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
Figure 1: Cancer Cachexia Pipeline by Phase, H1- 2018
Figure 2: Cancer Cachexia Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Cancer Cachexia Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Cancer Cachexia Pipeline by Phase, H1- 2018
Table 2: Cancer Cachexia Pipeline by Companies, H1- 2018 (1)
Table 3: Cancer Cachexia Pipeline by Mechanism of Action, H1- 2018
Table 4: ABREOS BIOSCIENCES, INC. - Cancer Cachexia Pipeline, H1- 2018
Table 5: AAVogen Cancer Cachexia Pipeline, H1- 2018
Table 6: Acacia Pharma Cancer Cachexia Pipeline, H1- 2018
Table 7: Aeterna Zentaris Inc. - Cancer Cachexia Pipeline, H1- 2018
Table 8: AVEO Oncology- Cancer Cachexia Pipeline, H1- 2018
Table 9: Energenesis Biomedical Co., Ltd - Cancer Cachexia Pipeline, H1- 2018
Table 10: Extend Biosciences - Cancer Cachexia Pipeline, H1- 2018
Table 11: Helsinn Healthcare, S.A - Cancer Cachexia Pipeline, H1- 2018
Table 12: Incyte Corporation - Cancer Cachexia Pipeline, H1- 2018
Table 13: Neomed - Cancer Cachexia Pipeline, H1- 2018
Table 14: NGM Biopharmaceuticals - Cancer Cachexia Pipeline, H1- 2018
Table 15: Paradigm Biopharma - Cancer Cachexia Pipeline, H1- 2018
Table 16: RaQualia Pharma - Cancer Cachexia Pipeline, H1- 2018
Table 17: StemMed Ltd - Cancer Cachexia Pipeline, H1- 2018
Table 18: TCI Peptide Therapeutics - Cancer Cachexia Pipeline, H1- 2018
Table 19: Viking Therapeutics - Cancer Cachexia Pipeline, H1- 2018
Table 1: Cancer Cachexia Pipeline by Phase, H1- 2018
Table 2: Cancer Cachexia Pipeline by Companies, H1- 2018 (1)
Table 3: Cancer Cachexia Pipeline by Mechanism of Action, H1- 2018
Table 4: ABREOS BIOSCIENCES, INC. - Cancer Cachexia Pipeline, H1- 2018
Table 5: AAVogen Cancer Cachexia Pipeline, H1- 2018
Table 6: Acacia Pharma Cancer Cachexia Pipeline, H1- 2018
Table 7: Aeterna Zentaris Inc. - Cancer Cachexia Pipeline, H1- 2018
Table 8: AVEO Oncology- Cancer Cachexia Pipeline, H1- 2018
Table 9: Energenesis Biomedical Co., Ltd - Cancer Cachexia Pipeline, H1- 2018
Table 10: Extend Biosciences - Cancer Cachexia Pipeline, H1- 2018
Table 11: Helsinn Healthcare, S.A - Cancer Cachexia Pipeline, H1- 2018
Table 12: Incyte Corporation - Cancer Cachexia Pipeline, H1- 2018
Table 13: Neomed - Cancer Cachexia Pipeline, H1- 2018
Table 14: NGM Biopharmaceuticals - Cancer Cachexia Pipeline, H1- 2018
Table 15: Paradigm Biopharma - Cancer Cachexia Pipeline, H1- 2018
Table 16: RaQualia Pharma - Cancer Cachexia Pipeline, H1- 2018
Table 17: StemMed Ltd - Cancer Cachexia Pipeline, H1- 2018
Table 18: TCI Peptide Therapeutics - Cancer Cachexia Pipeline, H1- 2018
Table 19: Viking Therapeutics - Cancer Cachexia Pipeline, H1- 2018
